Literature DB >> 9658198

Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant.

F Hervé1, G Caron, J C Duché, P Gaillard, N Abd Rahman, A Tsantili-Kakoulidou, P A Carrupt, P d'Athis, J P Tillement, B Testa.   

Abstract

Human alpha1-acid glycoprotein (AAG) is a mixture of at least two genetic variants: the A variant and the F1 and/or S variant or variants, which are encoded by two different genes. In a continuation of previous studies indicating specific drug transport roles for each AAG variant according to its separate genetic origin, this work was designed to (1) determine the affinities of the two main gene products of AAG (i.e., the A variant and a mixture of the F1 and S variants) for 35 chemically diverse drugs and (2) to obtain meaningful 3D-QSARs for each binding site. Affinities were obtained by displacement experiments, leading to qualitative indications about binding site characteristics. In particular, drugs binding selectively to the A variant displayed some common structural features, but this was not seen for the F1*S variants. Three-dimensional QSAR analyses using the CoMFA method yielded a steric model for binding to the A variant, from which a simplified haptophoric model was derived. In contrast, no statistically sound model was found for the F1*S variants, possibly due (among other reasons) to an insufficient number of high affinity ligands in the set.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658198     DOI: 10.1124/mol.54.1.129

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

1.  Role of biantennary glycans and genetic variants of human alpha1-acid glycoprotein in enantioselective binding of basic drugs as studied by high performance frontal analysis/capillary electrophoresis.

Authors:  Y Kuroda; Y Kita; A Shibukawa; T Nakagawa
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

2.  Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1*S forms.

Authors:  Koji Nishi; Tomomi Ono; Teruya Nakamura; Naoko Fukunaga; Miyoko Izumi; Hiroshi Watanabe; Ayaka Suenaga; Toru Maruyama; Yuriko Yamagata; Stephen Curry; Masaki Otagiri
Journal:  J Biol Chem       Date:  2011-02-24       Impact factor: 5.157

3.  Tryptophan residues play an important role in the extraordinarily high affinity binding interaction of UCN-01 to human alpha-1-acid glycoprotein.

Authors:  Masaaki Katsuki; Victor Tuan Giam Chuang; Koji Nishi; Ayaka Suenaga; Masaki Otagiri
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

4.  The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

Authors:  Marta Boffito; Patrick G Hoggard; Helen E Reynolds; Stefano Bonora; E Rhiannon Meaden; Alessandro Sinicco; Giovanni Di Perri; David J Back
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

5.  On-column entrapment of alpha1-acid glycoprotein for studies of drug-protein binding by high-performance affinity chromatography.

Authors:  Jeanethe Anguizola; Cong Bi; Michelle Koke; Abby Jackson; David S Hage
Journal:  Anal Bioanal Chem       Date:  2016-06-11       Impact factor: 4.142

6.  Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants.

Authors:  T Nakagawa; S Kishino; S Itoh; M Sugawara; K Miyazaki
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

7.  Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoprotein.

Authors:  Mohammad A K Azad; Johnny X Huang; Matthew A Cooper; Kade D Roberts; Philip E Thompson; Roger L Nation; Jian Li; Tony Velkov
Journal:  Biochem Pharmacol       Date:  2012-05-12       Impact factor: 5.858

8.  Drug-binding energetics of human α-1-acid glycoprotein assessed by isothermal titration calorimetry and molecular docking simulations.

Authors:  Johnny X Huang; Matthew A Cooper; Mark A Baker; Mohammad A K Azad; Roger L Nation; Jian Li; Tony Velkov
Journal:  J Mol Recognit       Date:  2012-12       Impact factor: 2.137

9.  Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097.

Authors:  Jianmei Wu; Patricia M Lorusso; Larry H Matherly; Jing Li
Journal:  Clin Cancer Res       Date:  2012-02-20       Impact factor: 12.531

10.  Canine orosomucoid (alpha-1 acid glycoprotein) variants and their influence on drug plasma protein binding.

Authors:  Ana P Costa; Michael H Court; Nicolas F Villarino; Neal S Burke; Katrina L Mealey
Journal:  J Vet Pharmacol Ther       Date:  2020-08-03       Impact factor: 1.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.